252.16

0.10% 0.25

Axsome Therapeutics Inc (AXSM)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché AXSM Giù? Forum Previsione

Precedente Chiudi:

$251.91

Aprire:

$251.13

Volume 24 ore:

519.42K

Relative Volume:

0.72

Capitalizzazione di mercato:

$12.98B

Reddito:

$708.24M

Utile/perdita netta:

$-188.30M

Rapporto P/E:

-67.44

EPS:

-3.7392

Flusso di cassa netto:

$-70.99M

1 W Prestazione:

+2.36%

1M Prestazione:

+10.73%

6M Prestazione:

+70.38%

1 anno Prestazione:

+148.19%

Intervallo 1D:

$248.64

$254.84

Intervallo di 1 settimana:

$247.69

$257.93

Portata 52W:

$96.09

$257.93

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Nome

Axsome Therapeutics Inc

Settore

Healthcare (1100)

Industria

Biotechnology (615)

Telefono

(212) 332-3241

Indirizzo

ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK

Dipendente

925

Cinguettio

Prossima data di guadagno

2026-08-03

Ultimi documenti SEC

AXSM's Discussions on Twitter

Compare AXSM vs VRTX, REGN, ARGX, ALNY, RVMD

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AXSM Axsome Therapeutics Inc	252.16	13.04B	708.24M	-188.30M	-70.99M	-3.7392
VRTX Vertex Pharmaceuticals Inc	458.99	114.33B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	607.93	64.47B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	892.26	54.99B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	282.72	38.42B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	157.77	34.03B	742.00K	-1.37B	-1.07B	-7.0731

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-02-24	Iniziato	Wolfe Research	Outperform
2026-01-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-10-01	Iniziato	B. Riley Securities	Buy
2025-09-03	Ripresa	Wells Fargo	Overweight
2025-07-03	Ripresa	Morgan Stanley	Overweight
2025-06-03	Iniziato	Oppenheimer	Outperform
2025-04-07	Iniziato	Jefferies	Buy
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-12-31	Reiterato	Mizuho	Outperform
2024-09-03	Iniziato	Wells Fargo	Overweight
2024-08-06	Aggiornamento	BofA Securities	Neutral → Buy
2024-07-22	Iniziato	Needham	Buy
2024-04-29	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-03-19	Iniziato	Robert W. Baird	Outperform
2024-02-06	Iniziato	UBS	Buy
2024-01-25	Iniziato	RBC Capital Mkts	Outperform
2023-12-13	Iniziato	Citigroup	Buy
2023-08-08	Aggiornamento	BofA Securities	Underperform → Neutral
2023-01-05	Iniziato	Piper Sandler	Neutral
2022-11-01	Iniziato	Loop Capital	Buy
2022-09-07	Ripresa	Mizuho	Buy
2021-08-10	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-06-10	Iniziato	Berenberg	Buy
2021-01-08	Iniziato	Jefferies	Buy
2020-12-16	Iniziato	Mizuho	Buy
2020-09-29	Iniziato	BofA Securities	Underperform
2020-09-10	Iniziato	Morgan Stanley	Overweight
2020-04-28	Reiterato	H.C. Wainwright	Buy
2020-04-14	Iniziato	Cowen	Outperform
2019-12-30	Reiterato	H.C. Wainwright	Buy
2019-12-17	Reiterato	H.C. Wainwright	Buy
2019-12-16	Reiterato	Guggenheim	Buy
2019-10-16	Iniziato	Guggenheim	Buy
2019-09-18	Iniziato	William Blair	Outperform
2019-05-28	Iniziato	SunTrust	Buy
2019-05-23	Reiterato	H.C. Wainwright	Buy
2019-04-08	Iniziato	SVB Leerink	Outperform
2019-03-15	Reiterato	H.C. Wainwright	Buy
2016-10-03	Ripresa	Brean Capital	Buy
2015-12-15	Iniziato	Cantor Fitzgerald	Buy
2015-12-14	Iniziato	Ladenburg Thalmann	Buy

Mostra tutto

Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie

Jun 16, 2026

3 Under-the-Radar Stocks to Buy and Hold for a Decade - The Motley Fool

Jun 16, 2026

Jun 15, 2026

Axsome presents data on narcolepsy treatments at sleep conference By Investing.com - Investing.com South Africa

Jun 15, 2026

Axsome presents data on narcolepsy treatments at sleep conference - Investing.com

Jun 15, 2026

Axsome Therapeutics Presents New Data on AXS-12 and Solriamfetol at SLEEP 2026 Conference - Quiver Quantitative

Jun 15, 2026

Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026 - GlobeNewswire

Jun 15, 2026

Axsome Therapeutics (AXSM) Stock Analysis: 57% Revenue Growth Propels Exciting Prospects - DirectorsTalk Interviews

Jun 15, 2026

Landscape Capital Management L.L.C. Sells 3,983 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 15, 2026

Jun 14, 2026

First Turn Management LLC Has $37.79 Million Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Nicholas Investment Partners LP Purchases 42,907 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Eventide Asset Management LLC Sells 175,172 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 14, 2026

Jun 13, 2026

The Technical Signals Behind (AXSM) That Institutions Follow - Stock Traders Daily

Jun 13, 2026

Rhenman & Partners Asset Management AB Reduces Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat

Jun 13, 2026

Jun 12, 2026

Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits

Jun 12, 2026

Jun 11, 2026

Axsome therapeutics director Roger Jeffs sells $141,655 in shares By Investing.com - Investing.com India

Jun 11, 2026

Axsome therapeutics director Roger Jeffs sells $141,655 in shares - Investing.com UK

Jun 11, 2026